We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 55.00 | 45.00 | 65.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMVRP
RNS Number : 3498E
Verona Pharma PLC
05 May 2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES ----------------------------------------------- 1. Identity of the issuer or Verona Pharma PLC the underlying issuer of existing shares to which voting rights are attached: ------------------------------------------------------------- ------------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): ---------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights x ---------------------------------------------------------------- ---------------------------- An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ---------------------------------------------------------------- ---------------------------- An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ---------------------------------------------------------------- ---------------------------- An event changing the breakdown of voting rights ---------------------------------------------------------------- ---------------------------- Other (please specify): --------------------------------------------------------- ----- ---------------------------- 3. Full name of person(s) OrbiMed Private Investments subject to the VI, LP notification obligation: ----------------------------------------------------------- --------------------------------- 4. Full name of shareholder(s) (if different from 3.): ----------------------------------------------------------- --------------------------------- 5. Date of the transaction May 2, 2017 and date on which the threshold is crossed or reached: ----------------------------------------------------------- --------------------------------- 6. Date on which issuer May 4, 2017 notified: ----------------------------------------------------------- --------------------------------- 7. Threshold(s) that is/are Greater than 10% ownership crossed or reached: ----------------------------------------------------------- --------------------------------- 8. Notified details: ------------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares ------------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the triggering of to the triggering transaction shares transaction if possible using the ISIN CODE ------------- -------------------------------- ------------------------------------------------------------------------ Number Number Number Number of % of voting of of of shares voting rights Shares Voting rights Rights ------------- --------------- --------------- -------------------------- ----------------------- ------------------- Direct Indirect Direct Indirect Direct Indirect ------------- ----------- ----------- ------------- ----------- ---------- ----------- -------- --------- GB00B06GSH43 4,669,847 4,669,847 4,669,847 4,669,847 4.72% --------------- --------------- ------------- ----------- ---------- ----------- -------- --------- US9250501064 5,333,328 5,333,328 5.39% ------------- --------------- --------------- ------------- ----------- ---------- ----------- -------- --------- B: Qualifying Financial Instruments ------------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ------------------------------------------------------------------------------------------------------------------------- Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument Period may be acquired if the instrument is exercised/ converted. ----------------- --------------- ---------------------------- ---------------------------------- ------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ------------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ------------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights instrument period refers to --------------- --------------- --------------- ----------- ------------------------- ------------------------------ Nominal Delta --------------- --------------- --------------- ----------- ------------------------- ------------------- --------- Total (A+B+C) ------------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights -------------------------------------------------------------- --------------------------------------------------------- 10,003,175 10.10% -------------------------------------------------------------- --------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: -------------------------------------------------------------------------------- These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("Advisors"), is the sole managing member of GP VI. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. Proxy Voting: -------------------------------------------------------------------------------- 10. Name of the proxy holder: ----------------------------------------------------------------- ------------- 11. Number of voting rights proxy holder will cease to hold: ----------------------------------------------------------------- ------------- 12. Date on which proxy holder will cease to hold voting rights: ----------------------------------------------------------------- ------------- 13. Additional information: ----------------------------------------------------------------- ------------- 14. Contact name: Douglas Coon ----------------------------------------------------------------- ------------- 15. Contact telephone number: 212-739-6400 ----------------------------------------------------------------- -------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUGUPGAUPMGGA
(END) Dow Jones Newswires
May 05, 2017 07:15 ET (11:15 GMT)
1 Year Verona Pharma Chart |
1 Month Verona Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions